Omeros 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Yartemlia generated $41.8 million in gross sales and $35.9 million in net sales in the 3rd quarter, its 2nd full quarter of sales; compared with the 2nd quarter, gross sales increased 30% and net sales increased 26%.
- Gross-to-net deductions rose to 14% of gross sales from 11.5% in the 2nd quarter, driven primarily by increased 340B sales.
- Omeros reported a GAAP net loss of $57.4 million, or $0.79 per share, compared with net income of $13.2 million, or $0.18 per share, in the 2nd quarter; non-GAAP adjusted net income was $4.7 million, or $0.06 per share, versus $1.8 million, or $0.02 per share.
- The 3rd quarter GAAP results included a $62 million non-cash mark-to-market loss on financial instruments associated with the 2029 convertible notes, compared with an $11.5 million net non-cash gain in the 2nd quarter.
- Omeros ended the 3rd quarter with $95.3 million in cash and investments and generated $13.3 million in net cash from operating activities, its 2nd consecutive quarter of positive operating cash flow.
- Omeros repurchased $30.5 million in aggregate principal amount of its 2029 convertible notes for $60.2 million, reducing outstanding principal by 43% to $40.3 million; the transactions reduced potential dilution by 4.9 million shares and eliminated $8.6 million in future interest payments.
- As of September 30th, 109 unique accounts had ordered Yartemlia, up from 73 at June 30th, and P&T committee approvals had reached 80% of the top 40 US transplant centers.
- Adult patients accounted for approximately 70% of Yartemlia utilization and pediatric patients for 30%; outpatient use increased, alongside greater 340B participation.
- Omeros said all appropriate claims of which it was aware had been paid by commercial payers, Medicare, or Medicaid, with coverage aligned with the product label.
- Yartemlia's NTAP, effective October 1st, provides up to $287,000 in additional Medicare reimbursement per eligible inpatient case; the company said Medicare beneficiaries represent approximately 30% of U.S. allogeneic transplant recipients.
- Yartemlia has transitional pass-through status through June 2029 and, according to the company, will remain exempt from the Medicare reimbursement change for affected 340B hospitals beginning January 1st, 2027.
- Omeros said the CHMP issued a negative opinion on its marketing authorization application for narsoplimab for Ta/TMA following reexamination; the company plans to focus regulatory efforts outside the European Union and pursue international access through reimbursed named patient programs in parts of Europe and other regions.
- Omeros reported that OMS-527's nonclinical work is underway and that it expects to begin enrollment in the inpatient clinical trial in early 2027, with trial data expected in 2027.
- The company said IND-enabling studies have begun for its TCAT platform and that a first-in-human trial of OMS-805 is targeted for late 2027.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website. I will now turn the call over to Jennifer Williams, Investor Relations for Omeros.
Please go ahead. Thank you, and good afternoon, everyone.
Before we begin, please note that today's discussion will include forward-looking statements. These statements reflect management's current expectations and beliefs as of today, and are subject to risks and uncertainties that could cause actual results to differ materially. For a detailed discussion of these risks and uncertainties, please refer to the special note regarding forward-looking statements and the risk factors sections in our quarterly report on Form 10-Q filed today with the SEC, as well as our most recent annual report on Form 10-K. Today's call will also include a discussion of certain non-GAAP financial measures. A reconciliation of these non-GAAP measures to the corresponding GAAP measures is included in Omeros' earnings press release issued earlier today, which is available on the Investor Relations page of our website and has been furnished with the Form 8-K we filed with the SEC earlier today.
With that, I'll turn the call over to Dr. Greg Demopulos, Chairman and CEO of Omeros.
Thank you, Jennifer, and good afternoon, everyone. Joining me today are David Borges, our Chief Accounting Officer, Dr. Kathy Melfi, our Chief Regulatory Officer, Dr. Steve Whitaker, Vice President of Clinical, and Bill Woodman, our Chief Commercial Officer. I'll begin with an overview of our third quarter operations and financial results, followed by program updates. David will then review the financials in more detail, after which we'll open the call for questions. Following FDA approval in December 2025, we launched YARTEMLEA in late January as the first and only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. YARTEMLEA is also the first and only approved inhibitor of the lectin pathway of complement. The third quarter marked just our second full quarter of YARTEMLEA sales, and we're pleased with our progress.
In the third quarter, YARTEMLEA generated $41.8 million in gross sales and $35.9 million in net sales, reflecting continued commercial momentum. Compared with the second quarter, gross sales increased 30%, and net sales increased 26%. As expected, gross-to-net deductions increased to 14% of gross sales from 11.5% in the second quarter, driven almost entirely by a substantial increase in 340B sales, consistent with our goals of increasing outpatient utilization of YARTEMLEA and expanding our customer base. That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow. As discussed in prior earnings calls, our reported GAAP financial results include mandatory non-cash mark-to-market adjustments associated with the embedded derivative in our 2029 convertible notes. A higher Omeros stock price increases the related non-cash expense.
Reflecting these non-cash adjustments, GAAP net loss for the third quarter was $57.4 million, or $0.79 per share, compared to net income of $13.2 million, or $0.18 per share in the second quarter. Excluding the non-cash remeasurements of the embedded derivatives and other financial instruments, non-GAAP adjusted net income for the third quarter was $4.7 million, or $0.06 per share, compared to second quarter net income of $1.8 million, or $0.02 per share. We ended the third quarter with $95.3 million in cash and investments. Most importantly, we generated $13.3 million in net cash from operating activities during the quarter, marking our second consecutive quarter of positive operating cash flow.
As a reminder, in July, we repurchased $30.5 million in aggregate principal amount of our 2029 convertible notes through two privately negotiated transactions for an aggregate of $60.2 million, reducing the outstanding principal amount by 43% to $40.3 million. These transactions also reduced potential dilution by 4.9 million shares and eliminated $8.6 million in future interest payments. We achieved this reduction at a weighted average cost of $12.21 per underlying conversion share. Including the repurchase of a little over 843,000 shares of common stock in the open market at $11.70 per share during the first half of 2026, we have reduced the number of outstanding or potentially issuable shares by 5.8 million year to date. Let's now look more closely at our YARTEMLEA launch. As we have discussed before, our launch is focused on four priorities.
One, educating transplant teams to recognize and treat TA-TMA earlier. Two, securing institutional access through pharmacy and therapeutics, or P&T committee approvals, and streamlined ordering. Three, ensuring timely and appropriate reimbursement, and helping centers understand YARTEMLEA's reimbursement advantages over off-label therapies. Four, demonstrating YARTEMLEA's economic value through health economics and outcomes research, or HEOR. Through these four priorities, we continue our work to shift clinical practice toward proactive screening for TA-TMA, rather than defaulting to a diagnosis of exclusion, and toward earlier identification and treatment of more patients, with the goal of improving outcomes. To continue advancing these priorities, we have expanded our educational team by adding members to our market development management and medical science liaison teams. This expansion will further strengthen our field medical and educational capabilities, and support scientific engagement with healthcare professionals across transplant centers nationwide.
In addition to physicians and pharmacists, we remain focused on supporting nurses. Nurses spend the most time with transplant patients and are often the first care team members to notice changes suggestive of TA-TMA. For this reason, we recently established a clinical nurse educator team of six nurses from top-tier transplant centers. These Omeros nurses will work directly with nurses in transplant centers across the country. Transplant centers have large nursing teams, and staff turnover, new hires, and rotating assignments create an ongoing need for training to reinforce recognition of the signs and symptoms of TA-TMA. Our nurse educators will help make TA-TMA awareness part of everyday transplant care, supporting more consistent identification and timely treatment with YARTEMLEA. Across our nurse educators, market development managers, and medical science liaisons, we have added a total of 10 positions to our field force educational team.
To further support our educational efforts, we are adding to our transplant physician, pharmacist, and nursing speaker programs by establishing a nephrology speaker bureau comprising both onconephrologists and general nephrologists. Nephrologists are actively involved in the diagnosis and management of TA-TMA. Kidney disease is the most common form of organ dysfunction in TA-TMA. Nephrologists are becoming increasingly well-versed in the role of the lectin pathway, and we expect the nephrology speaker bureau will meaningfully expand our educational reach while strengthening understanding of both YARTEMLEA and lectin pathway biology. Alongside these educational efforts, our field sales team is actively engaging all 175 U.S. transplant centers. As of September 30, 109 unique accounts had ordered YARTEMLEA, a 49% increase from 73 accounts at June 30. Following an outsized share of pediatric utilization in the first quarter, adult adoption accelerated in the second and third quarters.
Adult patients now account for approximately 70% of utilization, and pediatric patients for 30%. This mix continues to move toward the historical nationwide allogeneic transplant mix of 85% adult and 15% pediatric procedures. As previously discussed, outpatient use of YARTEMLEA also increased this quarter, as evidenced by greater 340B participation. This is good for patients, likely reflective of earlier treatment and potentially better outcomes. This is also good for transplant centers, given that reimbursement for approved drugs in the outpatient setting can range from average selling price, or ASP, plus 4.3% to ASP plus 10% or more. P&T committee approvals also increased by 25% across transplant centers nationwide during the third quarter. By September 30, YARTEMLEA had received P&T committee approvals at 80% of the top 40 U.S. transplant centers nationwide. Let's turn now to reimbursement and the payer experience.
To date, all appropriate claims of which we are aware have been paid by commercial payers, Medicare, or Medicaid, and coverage is fully aligned with the product label. Transplant centers are becoming increasingly aware of the new technology add-on payment, or NTAP, for YARTEMLEA, which became effective on October 1. The NTAP provides up to $287,000 in additional Medicare reimbursement per eligible inpatient case involving YARTEMLEA. This is particularly important because Medicare beneficiaries represent approximately 30% of all U.S. allogeneic transplant recipients. No off-label treatment for TA-TMA, whether branded or biosimilar, has an NTAP. This gives YARTEMLEA a distinct reimbursement advantage that can substantially reduce hospitals' net cost of treating eligible Medicare inpatients. YARTEMLEA's pass-through status also provides an important reimbursement advantage in the Medicare hospital outpatient setting. The Centers for Medicare and Medicaid Services, or CMS, recently issued a new rule on 340B reimbursement.
Beginning January 1, 2027, Medicare will generally reimburse affected hospitals for 340B-acquired drugs at average sales price, or ASP, minus 28%. Drugs with transitional pass-through status, however, are exempt from this change and will continue to be reimbursed at ASP plus 6% or ASP plus 4.3% after sequestration. Neither branded eculizumab nor ravulizumab has pass-through status. YARTEMLEA holds pass-through status through June 2029 and is therefore excluded from this reimbursement reduction. This preserves a substantial reimbursement advantage for YARTEMLEA over these branded off-label treatments when purchased under the 340B program and administered in affected Medicare hospital outpatient settings. In the outpatient setting for commercially insured patients, YARTEMLEA's higher price per dose also translates into greater dollar margins per dose than lower-priced off-label alternatives, whether branded or biosimilar. We believe YARTEMLEA offers better efficacy and safety than off-label treatments for TA-TMA.
These reimbursement advantages provide centers with additional financial incentives to use YARTEMLEA in both inpatient and outpatient settings. Our HEOR manuscript is being finalized with journal submission planned within the next few weeks. The analyses show favorable incremental cost-effectiveness ratios, or ICERs, for YARTEMLEA compared to best supportive care, eculizumab, and ravulizumab. We expect that these analyses will further demonstrate YARTEMLEA's clinical and economic value, supporting its continued adoption. The recognition of YARTEMLEA's importance to patients and the patient advocacy community is growing. In September, the National Organization for Rare Disorders, or NORD, honored Omeros with its 2026 Industry Innovation Award for YARTEMLEA. NORD is the nation's leading rare disease patient advocacy organization. We are also preparing for a strong presence at the upcoming annual Congress of the American Society of Hematology, a major international meeting for hematologists and transplant physicians.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
